CYP2C19
ER-positive breast cancer
Tamoxifen
cytochrome p450
personalized medicine
pharmacogenomics
Journal
Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
pmc-release:
09
03
2024
medline:
27
11
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
ppublish
Résumé
Breast cancer (BC) continues to be the most common cancer in the women worldwide. Since estrogen receptor (ER)-positive BC accounts for the majority of newly diagnosed cases, endocrine therapy is advised to utilize either tamoxifen (Tam) or aromatase inhibitors. The use of Tam as a monotherapy or in conjunction with an aromatase inhibitor following two or three years of endocrine therapy has long been recommended. When used adjuvantly, Tam medication reduces BC mortality and relapses, while it extends survival times in metastatic BC when used in conjunction with other treatments. Unfortunately, the efficiency of Tam varies considerably. This study was conducted to explore the influence of genetic polymorphisms in
Identifiants
pubmed: 37688505
doi: 10.1177/15353702231187640
pmc: PMC10666731
doi:
Substances chimiques
afimoxifene
17197F0KYM
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Tamoxifen
094ZI81Y45
Estrogens
0
Antineoplastic Agents, Hormonal
0
CYP2C19 protein, human
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1507-1517Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Clin Pharmacol Ther. 2006 Jan;79(1):103-13
pubmed: 16413245
Clin Breast Cancer. 2018 Oct;18(5):e863-e868
pubmed: 29482947
Br J Clin Pharmacol. 2011 May;71(5):737-50
pubmed: 21480951
Iran J Pharm Res. 2019 Spring;18(2):1097-1102
pubmed: 31531091
J Ayub Med Coll Abbottabad. 2008 Oct-Dec;20(4):22-5
pubmed: 19999196
Oncogene. 2006 Mar 13;25(11):1679-91
pubmed: 16550168
J Pharm Biomed Anal. 2013 Mar 25;76:13-20
pubmed: 23291438
Lancet. 1998 May 16;351(9114):1451-67
pubmed: 9605801
J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75
pubmed: 15159443
Breast Cancer. 2020 Nov;27(6):1168-1176
pubmed: 32562189
Genet Mol Res. 2011 Dec 05;10(4):3514-9
pubmed: 22180071
Breast Cancer Res Treat. 2004 May;85(2):151-9
pubmed: 15111773
Sci Rep. 2021 Jan 11;11(1):415
pubmed: 33432065
J Biol Chem. 1994 Jun 3;269(22):15419-22
pubmed: 8195181
Sci Rep. 2017 Aug 10;7(1):7727
pubmed: 28798474
Breast Cancer Res Treat. 2009 May;115(2):391-6
pubmed: 18521743
Breast Cancer Res Treat. 1982;2(2):123-38
pubmed: 6184101
Hum Genet. 2010 Jan;127(1):1-17
pubmed: 19823875
Pharmacogenomics. 2010 Oct;11(10):1367-75
pubmed: 21047200
Mol Pharmacol. 1994 Oct;46(4):594-8
pubmed: 7969038
Sci Rep. 2020 Mar 25;10(1):5480
pubmed: 32214176
Breast Cancer Res Treat. 2008 Jan;107(1):15-24
pubmed: 18043895
J Clin Oncol. 2007 Nov 20;25(33):5187-93
pubmed: 18024866
Sci Rep. 2018 Apr 12;8(1):5913
pubmed: 29651133
Br J Clin Pharmacol. 2002 Aug;54(2):157-67
pubmed: 12207635
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
J Adv Pract Oncol. 2013 Jul;4(4):263-8
pubmed: 25032007
Int J Environ Res Public Health. 2020 Feb 20;17(4):
pubmed: 32093283